COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

University of Oxford/AstraZeneca - ChAdOx1 nCoV-19 vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-02-25)

Evidence profile
2021-02-26

Summary of findings
2021-02-26

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04400838
AstraZeneca + University of Oxford
Emary K, Lancet, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

MenACWY

RCT
Phase 2-3
Adults seronegative at baseline enrolled at 19 study sites in UK N=10673
Some concerns
Details

Full description

NCT04324606; ISRCTN1
University of Oxford/AstraZeneca
Folegatti PM, Lancet, 2020
COV001

Full text
Commentary
; Commentary
(20)31611-1/fulltext
Non replicating viral vector

ChAdOx1 SD

MenACWY

RCT
Phase 1 - 2
Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK N=1067
Low
Details

Full description

NCT04444674
University of Oxford/AstraZeneca
Madhi S, N Engl J Med, 2021
COV005

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa N=2026
Some concerns
Details

Full description

NCT04444674, PACTR202006922165132
AstraZeneca + University of Oxford
Madhi S, Research square , 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1 nCoV-19

Placebo D0/28

RCT
Phase 1-2
Adults living with HIV in 7 centers in South Africa N=104
Some concerns
Details

Full description

ISRCTN89951424
University of Oxford/AstraZeneca
Voysey M, Lancet, 2020
COV003

Full text
Commentary
Non replicating viral vector

ChAdOx1 SD/SD

MenACWY/saline

RCT
Phase 3
Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil N=10002
Some concerns
Details

Full description

NCT04400838
University of Oxford/AstraZeneca
Voysey M, Lancet, 2020
COV002

Full text
Commentary
Non replicating viral vector

ChAdOx1 LD/SD

ChAdOx1 SD/SD

MenACWY

RCT
Phase 2/3
Healthy adults in 18 centres in the UK N=10673
Some concerns
Details

Full description

NCT04324606 / EudraC
AstraZeneca + University of Oxford
Voysey M, Lancet, 2021
COV001/COV002/COV003/COV005

Full text
Commentary
; Commentary
; Commentary
Non replicating viral vector

ChAdOx1

MenACWY/saline

RCT
phase 1/2/3
Adults seronegative at baseline from four studies in multiple centres in Brazil, South Africa, and the UK N=24422
Some concerns
Details

Full description